Skip to main content
. 2022 Jan-Mar;14(1):40–53. doi: 10.32607/actanaturae.11523

Fig. 4.

Fig. 4

The classical scheme of antitumor vaccination with mouse tumor cells treated with a potential ICD inducer, followed by re-vaccination with viable tumor cells of the same type